CryoPort, Inc. (NASDAQ:CYRX) Given Average Rating of “Moderate Buy” by Brokerages

CryoPort, Inc. (NASDAQ:CYRX) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $18.00.

Several equities research analysts have recently commented on CYRX shares. Roth Capital reiterated a “buy” rating and set a $21.00 price target on shares of CryoPort in a research report on Friday, August 7th. Weiss Ratings lowered shares of CryoPort from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 17th. Guggenheim lifted their target price on shares of CryoPort from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Craig Hallum upped their target price on shares of CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, June 3rd. Finally, Jefferies Financial Group set a $13.50 price target on CryoPort in a research note on Monday, June 8th.

CryoPort Stock Performance

Shares of NASDAQ CYRX opened at $17.02 on Monday. CryoPort has a 1-year low of $7.61 and a 1-year high of $17.20. The company has a market cap of $862.06 million, a PE ratio of -18.91 and a beta of 1.89. The company has a 50-day moving average of $15.78 and a two-hundred day moving average of $13.36.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $48.97 million during the quarter, compared to the consensus estimate of $48.18 million. CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%. As a group, equities research analysts forecast that CryoPort will post -0.83 earnings per share for the current year.

Insider Activity at CryoPort

In other news, CEO Jerrell Shelton sold 28,800 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total transaction of $429,408.00. Following the completion of the transaction, the chief executive officer directly owned 1,201,814 shares in the company, valued at approximately $17,919,046.74. The trade was a 2.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is currently owned by company insiders.

Institutional Trading of CryoPort

Several hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP bought a new stake in shares of CryoPort in the second quarter worth $8,398,000. Squarepoint Ops LLC boosted its stake in shares of CryoPort by 685.1% during the 2nd quarter. Squarepoint Ops LLC now owns 368,424 shares of the company’s stock worth $5,784,000 after buying an additional 321,497 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of CryoPort during the 2nd quarter worth about $3,363,000. Granahan Investment Management LLC grew its holdings in shares of CryoPort by 475.0% in the 1st quarter. Granahan Investment Management LLC now owns 231,138 shares of the company’s stock valued at $1,914,000 after acquiring an additional 190,938 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of CryoPort by 62.9% in the first quarter. Renaissance Technologies LLC now owns 368,110 shares of the company’s stock valued at $3,048,000 after buying an additional 142,070 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Company Profile

Cryoport, Inc (NASDAQ: CYRX) provides temperature-controlled logistics and supply-chain solutions for the life sciences industry. The company supports the transportation, storage and management of sensitive biological materials, including cell and gene therapies, biologics, vaccines, clinical-trial materials and reproductive tissues.

Its offerings include specialized cryogenic and refrigerated shipping systems, monitoring and tracking technologies, logistics coordination, packaging and storage services, and related bioservices.